Full Text Journal Articles by
Author Ivan Milanov

Advertisement

Find full text journal articles






Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity.

Dirk Dressler, Maria Concetta Altavista, Eckart Altenmueller, Roongroj Bhidayasiri, Saeed Bohlega, Pedro Chana, Tae Mo Chung, Carlo Colosimo, Klemens Fheodoroff, Pedro J Garcia-Ruiz, Beomseok Jeon, Lingjing Jin, Petr Kanovsky, Ivan Milanov, Federico Micheli, Olga Orlova, Sanjay Pandey, Zvezdan Pirtosek, Maja Relja, Raymond Rosales, José Alberto Sagástegui-Rodríguez, Gholam Ali Shahidi, Sofia Timerbaeva, Xinhua Wan, Uwe Walter, Fereshte Adib Saberi,

Botulinum toxin (BT) therapy is a complex and highly individualised therapy defined by treatment algorithms and injection schemes describing its target muscles and their dosing. Various consensus guidelines have tried to standardise and to improve BT therapy. We wanted to update and improve consensus guidelines by: (1) Acknowledging recent advances ... Read more >>

J Neural Transm (Vienna) (Journal of neural transmission (Vienna, Austria : 1996))
[2021, 128(3):321-335]

Cited: 0 times

View full text PDF listing >>



Translation, adaptation and validation of the Bulgarian version of the King’s Parkinson’s Disease Pain Scale

Galina Stoyanova-Piroth, Ivan Milanov, Katerina Stambolieva,

<h4>Introduction: </h4> The purpose of the present study was to translate and cross-culturally adapt the King's Parkinson's Disease Pain Scale (KPPS) into Bulgarian and to investigate its psychometric properties in order to provide a validated Parkinson’s disease-specific pain instrument in Bulgarian language (KPPS-BG). <h4>Methods: </h4> Translation into Bulgarian and a ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Advertisement

Ofatumumab versus Teriflunomide in Multiple Sclerosis.

Stephen L Hauser, Amit Bar-Or, Jeffrey A Cohen, Giancarlo Comi, Jorge Correale, Patricia K Coyle, Anne H Cross, Jerome de Seze, David Leppert, Xavier Montalban, Krzysztof Selmaj, Heinz Wiendl, Cecile Kerloeguen, Roman Willi, Bingbing Li, Algirdas Kakarieka, Davorka Tomic, Alexandra Goodyear, Ratnakar Pingili, Dieter A Häring, Krishnan Ramanathan, Martin Merschhemke, Ludwig Kappos, ,

<h4>Background</h4>Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation. The relative effects of these two drugs in patients with multiple sclerosis are not known.<h4>Methods</h4>In two double-blind, double-dummy, phase 3 trials, we randomly assigned patients with relapsing multiple ... Read more >>

N Engl J Med (The New England journal of medicine)
[2020, 383(6):546-557]

Cited: 9 times

View full text PDF listing >>



Palliative care in multiple sclerosis: European guideline.

Alessandra Solari, David Oliver, ,

Mult Scler (Multiple sclerosis (Houndmills, Basingstoke, England))
[2020, 26(9):1009-1011]

Cited: 1 time

View full text PDF listing >>



EAN Guideline on Palliative Care of People with Severe, Progressive Multiple Sclerosis.

Alessandra Solari, Andrea Giordano, Jaume Sastre-Garriga, Sascha Köpke, Anne C Rahn, Ingo Kleiter, Katina Aleksovska, Mario A Battaglia, Jette Bay, Massimiliano Copetti, Jelena Drulovic, Liesbeth Kooij, John Mens, Edwin R Meza Murillo, Ivan Milanov, Ron Milo, Tatiana Pekmezovic, Janine Vosburgh, Eli Silber, Simone Veronese, Francesco Patti, Raymond Voltz, David J Oliver,

<b><i>Background and Purpose:</i></b> Patients with severe, progressive multiple sclerosis (MS) have complex physical and psychosocial needs, typically over several years. Few treatment options are available to prevent or delay further clinical worsening in this population. The objective was to develop an evidence-based clinical practice guideline for the palliative care of ... Read more >>

J Palliat Med (Journal of palliative medicine)
[2020, 23(11):1426-1443]

Cited: 0 times

View full text PDF listing >>



Safety of adjunctive treatment with cenobamate in patients with uncontrolled focal seizures - Authors' reply.

Gregory L Krauss, Pavel Klein, Christian Brandt, Sang Kun Lee, Ivan Milanov, Maja Milovanovic, Bernhard J Steinhoff, Marc Kamin,

Lancet Neurol (The Lancet. Neurology)
[2020, 19(4):288-289]

Cited: 0 times

View full text PDF listing >>



Diagnostic and Therapeutic Errors in Classical Trigeminal Neuralgia: a Multicenter Survey

Fabio Antonaci, Sebastiano Arceri, Martin Rakusa, Dimos Mitsikostas, Ivan Milanov, Vasil Todorov, Matteo Cotta Ramusino, Alfredo Costa,

<h4>Background: </h4> Classical Trigeminal neuralgia (CTN) is a severe, disabling form of painful cranial neuropathy. Even though CTN has a typical clinical picture, diagnosis it is often missed or delayed in clinical practice. This study was carried over to investigate the occurrence of diagnostic and therapeutic errors in CNT. Methods ... Read more >>

()
[, :]

Cited: 0 times

View full text PDF listing >>



Update on the Management of Parkinson's Disease for General Neurologists.

Zvezdan Pirtošek, Ovidiu Bajenaru, Norbert Kovács, Ivan Milanov, Maja Relja, Matej Skorvanek,

Management of Parkinson's disease (PD) is complicated due to its progressive nature, the individual patient heterogeneity, and the wide range of signs, symptoms, and daily activities that are increasingly affected over its course. The last 10-15 years have seen great progress in the identification, evaluation, and management of PD, particularly ... Read more >>

Parkinsons Dis (Parkinson's disease)
[2020, 2020:9131474]

Cited: 2 times

View full text PDF listing >>



Enhancing and accelerating stroke treatment in Eastern European region: Methods and achievement of the ESO EAST program.

Robert Mikulík, Valeria Caso, Natan M Bornstein, Veronika Svobodová, Francesca Romana Pezzella, Andreea Grecu, Steven Simsic, Zuzana Gdovinova, Anna Członkowska, Tamara S Mishchenko, Yuriy Flomin, Ivan G Milanov, Silva Andonova, Cristina Tiu, Anita Arsovska, Hrvoje Budinčević, Stanislav A Groppa, Daniel Bereczki, Janika Kõrv, Tatiana Kharitonova, Milan R Vosko,

Introduction:Despite the availability of prevention and therapies of stroke, their implementation in clinical practice, even of low-cost ones, remains poor. In 2015, the European Stroke Organisation (ESO) initiated the ESO Enhancing and Accelerating Stroke Treatment (EAST) program, which aims to improve stroke care quality, primarily in Eastern Europe. Here, we ... Read more >>

Eur Stroke J (European stroke journal)
[2020, 5(2):204-212]

Cited: 0 times

View full text PDF listing >>



Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial.

Gregory L Krauss, Pavel Klein, Christian Brandt, Sang Kun Lee, Ivan Milanov, Maja Milovanovic, Bernhard J Steinhoff, Marc Kamin,

<h4>Background</h4>More than a third of patients with epilepsy are treatment resistant, and thus new, more effective therapies to achieve seizure freedom are needed. Cenobamate (YKP3089), an investigational antiepileptic drug, has shown broad-spectrum anticonvulsant activity in preclinical studies and seizure models. We aimed to evaluate the safety, efficacy, and tolerability of ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2020, 19(1):38-48]

Cited: 6 times

View full text PDF listing >>



Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Ludwig Kappos, Amit Bar-Or, Bruce A C Cree, Robert J Fox, Gavin Giovannoni, Ralf Gold, Patrick Vermersch, Douglas L Arnold, Sophie Arnould, Tatiana Scherz, Christian Wolf, Erik Wallström, Frank Dahlke, ,

BACKGROUND:No treatment has consistently shown efficacy in slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS). We assessed the effect of siponimod, a selective sphingosine 1-phosphate (S1P) receptor1,5 modulator, on disability progression in patients with SPMS. METHODS:This event-driven and exposure-driven, double-blind, phase 3 trial was done at 292 ... Read more >>

Lancet (Lancet (London, England))
[2018, 391(10127):1263-1273]

Cited: 109 times

View full text PDF listing >>



Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry.

Angelo Antonini, Werner Poewe, K Ray Chaudhuri, Robert Jech, Barbara Pickut, Zvezdan Pirtošek, Jozsef Szasz, Francesc Valldeoriola, Christian Winkler, Lars Bergmann, Ashley Yegin, Koray Onuk, David Barch, Per Odin, ,

<h4>Introduction</h4>This registry evaluated the 24-month safety and efficacy of levodopa-carbidopa intestinal gel (LCIG) treatment in advanced Parkinson's disease (PD) patients under routine clinical care.<h4>Methods</h4>Motor fluctuations, dyskinesia, non-motor symptoms, quality of life, and safety were evaluated. Observations were fully prospective for treatment-naïve patients (60% of patients) and partially retrospective for patients ... Read more >>

Parkinsonism Relat Disord (Parkinsonism & related disorders)
[2017, 45:13-20]

Cited: 32 times

View full text PDF listing >>



Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Xavier Montalban, Stephen L Hauser, Ludwig Kappos, Douglas L Arnold, Amit Bar-Or, Giancarlo Comi, Jérôme de Seze, Gavin Giovannoni, Hans-Peter Hartung, Bernhard Hemmer, Fred Lublin, Kottil W Rammohan, Krzysztof Selmaj, Anthony Traboulsee, Annette Sauter, Donna Masterman, Paulo Fontoura, Shibeshih Belachew, Hideki Garren, Nicole Mairon, Peter Chin, Jerry S Wolinsky, ,

<h4>Background</h4>An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the primary progressive form of the disease.<h4>Methods</h4>In this phase 3 trial, we randomly assigned 732 patients with ... Read more >>

N Engl J Med (The New England journal of medicine)
[2017, 376(3):209-220]

Cited: 356 times

View full text PDF listing >>



Efficacy and safety of lacosamide as first add-on or later adjunctive treatment for uncontrolled partial-onset seizures: A multicentre open-label trial.

Wendy Waldman Zadeh, Antonio Escartin, William Byrnes, Frank Tennigkeit, Simon Borghs, Ting Li, Peter Dedeken, Marc De Backer, ,

<h4>Purpose</h4>To evaluate the efficacy and safety of lacosamide administered as either first add-on or later add-on antiepileptic drug (AED) therapy for patients with uncontrolled partial-onset seizures (POS).<h4>Methods</h4>In this open-label, multicentre trial, patients with POS initiated oral lacosamide (titrated to 400 mg/day) either as add-on to first AED monotherapy, or as ... Read more >>

Seizure (Seizure)
[2015, 31:72-79]

Cited: 16 times

View full text PDF listing >>



European Headache Federation consensus on technical investigation for primary headache disorders.

D D Mitsikostas, M Ashina, A Craven, H C Diener, P J Goadsby, M D Ferrari, C Lampl, K Paemeleire, J Pascual, A Siva, J Olesen, V Osipova, P Martelletti, ,

The diagnosis of primary headache disorders is clinical and based on the diagnostic criteria of the International Headache Society (ICHD-3-beta). However several brain conditions may mimic primary headache disorders and laboratory investigation may be needed. This necessity occurs when the treating physician doubts for the primary origin of headache. Features ... Read more >>

J Headache Pain (The journal of headache and pain)
[2015, 17:5]

Cited: 23 times

View full text PDF listing >>



ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.

Gabriel Boeru, Ivan Milanov, Francesca De Robertis, Wojciech Kozubski, Michael Lang, Sònia Rojas-Farreras, Mark Tomlinson,

<h4>Background</h4>The ExtaviJect® 30G autoinjector was developed to facilitate parenteral self-administration of interferon beta-1b (Extavia®), a first-line disease-modifying therapy in patients with multiple sclerosis. Our aim was to assess patient compliance with treatment when using the autoinjector, patients' and nurses' experiences of using the device, its tolerability, and patient satisfaction.<h4>Methods</h4>This was ... Read more >>

Med Devices (Auckl) (Medical devices (Auckland, N.Z.))
[2013, 6:175-184]

Cited: 11 times

View full text PDF listing >>



Pegylated interferon β-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.

Peter A Calabresi, Bernd C Kieseier, Douglas L Arnold, Laura J Balcer, Alexey Boyko, Jean Pelletier, Shifang Liu, Ying Zhu, Ali Seddighzadeh, Serena Hung, Aaron Deykin, ,

<h4>Background</h4>Subcutaneous pegylated interferon (peginterferon) beta-1a is being developed for treatment of relapsing multiple sclerosis, with less frequent dosing than currently available first-line injectable treatments. We assessed the safety and efficacy of peginterferon beta-1a after 48 weeks of treatment in the placebo-controlled phase of the ADVANCE trial, a study of patients ... Read more >>

Lancet Neurol (The Lancet. Neurology)
[2014, 13(7):657-665]

Cited: 138 times

View full text PDF listing >>



Chromosomal radiosensitivity in patients with multiple sclerosis.

Maria Milenkova, Ivan Milanov, Ksenia Kmetska, Sofia Deleva, Ljubomira Popova, Valeria Hadjidekova, Violeta Groudeva, Savina Hadjidekova, Inmaculada Domínguez,

Multiple sclerosis is a clinically heterogeneous autoimmune disease leading to severe neurological disability. Although during the last years many disease-modifying agents as treatment options for multiple sclerosis have been made available, their mechanisms of action are still not fully determined. In the present study radiosensitivity in lymphocytes of patients with ... Read more >>

Mutat Res (Mutation research)
[2013, 749(1-2):3-8]

Cited: 2 times

View full text PDF listing >>



Diagnostic value of combinations of symptoms of migraine and tension-type headache included in the diagnostic criteria for children and adolescents in the International Classification of Headache Disorders 2nd Edition.

Iliyana H Pacheva, Ivan G Milanov, Ivan S Ivanov, Rumen S Stefanov,

AIM:To suggest diagnostic combinations of symptoms for migraine and tension type headache (TTH), and for differentiation of overlapping headache (classified as either migraine or TTH) through evaluation of the diagnostic value of combinations of characteristics included in the International Headache Society diagnostic criteria for migraine and TTH in children and ... Read more >>

Folia Med (Plovdiv) (Folia medica)
[2013, 55(3-4):46-55]

Cited: 2 times

View full text PDF listing >>



How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple sclerosis?

Franz Fazekas, Ovidiu Bajenaru, Thomas Berger, Tanja Hojs Fabjan, Alenka Horvat Ledinek, Gábor Jakab, Samuel Komoly, Tetiana Kobys, Jörg Kraus, Egon Kurča, Theodoros Kyriakides, L'ubomír Lisý, Ivan Milanov, Tetyana Nehrych, Sergii Moskovko, Panayiotis Panayiotou, Saša Šega Jazbec, Larysa Sokolova, Radomír Taláb, Latchezar Traykov, Peter Turčáni, Karl Vass, Norbert Vella, Nataliya Voloshyná, Eva Havrdová,

Multiple sclerosis (MS) is a neurological disorder characterized by inflammatory demyelination and neurodegeneration in the central nervous system. Until recently, disease-modifying treatment was based on agents requiring parenteral delivery, thus limiting long-term compliance. Basic treatments such as beta-interferon provide only moderate efficacy, and although therapies for second-line treatment and highly ... Read more >>

Front Neurol (Frontiers in neurology)
[2013, 4:10]

Cited: 11 times

View full text PDF listing >>



Fingolimod in the treatment algorithm of relapsing remitting multiple sclerosis: a statement of the Central and East European (CEE) MS Expert Group.

Franz Fazekas, Thomas Berger, Tanja Hojs Fabjan, Alenka Horvat Ledinek, Gábor Jakab, Samuel Komoly, Jörg Kraus, Egon Kurča, Theodoros Kyriakides, L'ubomír Lisý, Ivan Milanov, Panayiotis Panayiotou, Sasa Sega Jazbec, Radomír Taláb, Latchezar Traykov, Peter Turčáni, Karl Vass, Norbert Vella, Eva Havrdová,

Fingolimod is the first oral treatment of multiple sclerosis. It is the first-in-class sphingosine 1-phosphate receptor modulator that binds to sphingosine 1-phophate receptors on lymphocytes and via downregulation of the receptor prevents lymphocyte egress from lymphoid tissues into the circulation. This mechanism reduces the infiltration of potentially auto-aggressive lymphocytes into ... Read more >>

Wien Med Wochenschr (Wiener medizinische Wochenschrift (1946))
[2012, 162(15-16):354-366]

Cited: 7 times

View full text PDF listing >>



Prevalence of dementia and mild cognitive impairment in a Bulgarian urban population.

Ivan Dimitrov, Christophe Tzourio, Ivan Milanov, Nadezhda Deleva, Latchezar Traykov,

<h4>Background</h4>Prevalence of cognitive impairment and dementia has not been studied in Bulgaria up to date. A 2-phase cross-sectional study was designed in order to determine the prevalence of dementia, its subtypes, and mild cognitive impairment in a Bulgarian population.<h4>Methods</h4>The study sample consisted of 605 participants over the age of 65, ... Read more >>

Am J Alzheimers Dis Other Demen (American journal of Alzheimer's disease and other dementias)
[2012, 27(2):131-135]

Cited: 4 times

View full text PDF listing >>



Mesencephalic form of meningoencephalitis in a patient with HLA-B51 Behçet's disease: case report.

Marko Klissurski, Ivan Milanov, Paraskeva Stamenova, Petranka Troyanova, Evguenia Vassileva, Pavlina Dulguerova,

This case report is a detailed description of the clinical, laboratory, imaging and therapeutic characteristics of the sixth patient with neuro-Behçet's disease reported by Bulgarian authors. The diagnosis was made in accordance with the international diagnostic criteria for Behçet's disease and was verified by skin biopsy. Therapeutic response was followed ... Read more >>

Acta Clin Croat (Acta clinica Croatica)
[2011, 50(3):435-441]

Cited: 0 times

View full text PDF listing >>



Transient mutism and pathologic laughter in the course of cerebellitis.

Petia S Dimova, Veneta S Bojinova, Ivan G Milanov,

The phenomenon of cerebellar mutism with subsequent dysarthria is most commonly described as a part of posterior fossa syndrome after surgery for neoplasms in childhood. Pathologic laughter, on the other hand, is observed primarily in various neurologic diseases in adults. In the present case, a child manifested transient mutism and ... Read more >>

Pediatr Neurol (Pediatric neurology)
[2009, 41(1):49-52]

Cited: 13 times

View full text PDF listing >>



Determination of plasma aminothiols by high performance liquid chromatography after precolumn derivatization with N-(2-acridonyl)maleimide.

Bistra Benkova, Valentin Lozanov, Ivaylo P Ivanov, Antonia Todorova, Ivan Milanov, Vanio Mitev,

Design, synthesis and properties of new derivatization reagent N-(2-acridonyl)-maleimide (MIAC) for thiol groups is presented. The reaction of MIAC with aminothiols is specific, very fast and yield highly fluorescent products. The HPLC method for determination of homocysteine, cysteine and glutathione based on utilization of MIAC is developed. A baseline separation ... Read more >>

J Chromatogr B Analyt Technol Biomed Life Sci (Journal of chromatography. B, Analytical technologies in the biomedical and life sciences)
[2008, 870(1):103-108]

Cited: 18 times

View full text PDF listing >>



Advertisement

Disclaimer
1.2401 s